Phase I cancer trials: A crucible of competing priorities

International Anesthesiology Clinics

Volumn 39, Issue 3, 2001, Pages 13-33

  Miller, M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RESEARCH; CLINICAL TRIAL; DOCTOR PATIENT RELATION; HUMAN; MEDICAL ETHICS; PATIENT CARE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0034821660     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004311-200107000-00004     Document Type: Review

References (65)

1. The ethical analysis of clinical trials: New lessons for and from cancer research
2. Philosophical reflections on human experimentation
3. The therapeutic misconception: Informed consent in psychiatric research
4. Physician-investigator/patient-subject: Exploring the logic and the tension
5. Clinical trials of antitumor agents: Experimental design and timeline considerations
6. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents
7. Current Phase I/II designs: Are they adequate?
8. Using toxicity grades in the design and analysis of cancer phase I clinical trials
9. Clinical trials for the evaluation of cancer therapy
10. Early cancer clinical trials: Safety, numbers, and consent
11. A response to a purported ethical difficulty with randomized clinical trials involving cancer patients
12. Responses and toxic deaths in phase I clinical trials
13. Phase I Trial design: Are new methodologies being put into practice?
14. Bayesian methods for phase I clinical trials
15. Design and analysis of phase I clinical trials
16. Design and conduct of phase I trials
17. EORTC guidelines for phase I trials with single agents in adults
18. Design of phase I and II clinical trials in cancer: A statistician's view
19. Phase I clinical trials
20. Workshop on phase I study design
21. Design of phase I and II clinical trials in cancer: A statistician's view
22. Model-guided determination of maximum tolerated dose in phase I clinical trials: Evidence for increased precision
23. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics
24. Design and results of phase I cancer clinical trials: Three-year experience at M.D. Anderson Cancer Center
25. Choice of starting dose and escalation for phase I studies of antitumor agents
26. Therapeutic response in phase I trials of antineoplastic agents
27. Prognostic factors for survival in patients treated in phase I clinical trials
28. Study of cohort-specific consent and patient control in phase I cancer trials
29. Perceptions of cancer patients and their physicians involved in phase I trials
30. Informed consent, the cancer patient, and phase I clinical trials
31. Patient motivation and informed consent in a phase I study of an anticancer agent
32. The impact of disease severity on the informed consent process in clinical research
33. False hopes and best data: Consent to research and the therapeutic misconception
34. Informed consent for phase I studies: Evaluation of quantity and quality of information provided to patients
35. Proposing phase I studies: Patients', relatives', nurses' and specialists' perceptions
36. Informing patients about phase I trials: How should it be done?
37. Trust - The fragile foundation of contemporary biomedical research
38. Human experimentation and human rights
39. Ethics and clinical research revisited. A tribute to Henry K. Beecher
40. Questing for grails: Duplicity, betrayal, and self-deception in post modern medical research
41. Informed consent - Must it remain a fairy tale?
42. Continual reassessment method: A practical design for phase I clinical trials in cancer
43. Sequential design and analysis of dose finding studies in patients with life threatening disease
44. Methods for dose finding studies in cancer clinical trials: A review and results of a Monte Carlo study
45. Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer
46. Improved designs for dose escalation studies using pharmacokinetic measurements
47. Physician-determined patient risk of toxic effects: Impact on enrollment and decision making in phase I cancer trials
48. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses
49. Sequential search for an optimal dosage
50. Some practical improvements in the continual reassessment method for phase I studies
51. Practical modifications of the continual reassessment method for phase I cancer clinical trials
52. Phase I cancer trials: A collusion of misunderstanding
53. Collusion in doctor-patient communication about imminent death: An ethnographic study
54. Phase I cancer trials - Therapeutic research?
55. Phase I cancer trials - Therapeutic research?
56. Experimental treatment. Oxymoron or aspiration?
57. The meaning of professionalism: Doctors' ethics and biomedical science
58. Cohort-specific consent: An honest approach to phase I cancer studies
59. Informed consent for investigational chemotherapy: Patients' and physicians' perceptions
60. Phase I oncology trials